The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility
Both nations deepen cooperation in health innovation, AI-driven healthcare, biomedical research, data sharing, and life sciences to accelerate next-generation healthcare solutions
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Samelisant will be the centerpiece of Suven’s scientific presence
The decision was driven by results from the Phase III CAPItello-281 trial,
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
